MXPA05010597A - Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi. - Google Patents

Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.

Info

Publication number
MXPA05010597A
MXPA05010597A MXPA05010597A MXPA05010597A MXPA05010597A MX PA05010597 A MXPA05010597 A MX PA05010597A MX PA05010597 A MXPA05010597 A MX PA05010597A MX PA05010597 A MXPA05010597 A MX PA05010597A MX PA05010597 A MXPA05010597 A MX PA05010597A
Authority
MX
Mexico
Prior art keywords
breast cancer
hydroxy tamoxifen
prevention
treatment
patients
Prior art date
Application number
MXPA05010597A
Other languages
English (en)
Spanish (es)
Inventor
Philippe Rouanet
Original Assignee
Lab Besins Internat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Besins Internat filed Critical Lab Besins Internat
Publication of MXPA05010597A publication Critical patent/MXPA05010597A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MXPA05010597A 2003-04-01 2003-12-15 Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi. MXPA05010597A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45896303P 2003-04-01 2003-04-01
PCT/EP2003/015029 WO2004087123A1 (en) 2003-04-01 2003-12-15 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
MXPA05010597A true MXPA05010597A (es) 2006-03-09

Family

ID=33131847

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010597A MXPA05010597A (es) 2003-04-01 2003-12-15 Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.

Country Status (11)

Country Link
US (2) US7704516B2 (https=)
EP (3) EP1608353B1 (https=)
JP (1) JP5490346B2 (https=)
AU (1) AU2003294973B2 (https=)
CA (1) CA2519980C (https=)
ES (3) ES2456958T3 (https=)
IL (1) IL170807A (https=)
MX (1) MXPA05010597A (https=)
NO (1) NO333805B1 (https=)
NZ (1) NZ542499A (https=)
WO (1) WO2004087123A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327363D1 (de) * 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
MXPA05006526A (es) * 2002-12-18 2006-02-17 Besins Int Lab Tratamiento de mastalgia con 4-hidroxi tamoxifen.
ES2456958T3 (es) * 2003-04-01 2014-04-24 Besins Healthcare Luxembourg Sarl Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
JP4682129B2 (ja) * 2003-06-09 2011-05-11 アセンド セラピュティクス インコーポレイテッド ４−ヒドロキシタモキシフェンによる過剰瘢痕化の治療及び予防
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
PT1748770E (pt) * 2004-03-22 2008-07-16 Besins Int Lab Tratamento e prevenção de doença benigna da mama com 4-hidroxi-tamoxifeno
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EA011295B1 (ru) * 2004-10-14 2009-02-27 Лаборатуар Безен Энтернасьональ Рецептура геля с 4-гидрокситамоксифеном
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
EP4220178A3 (en) * 2014-05-12 2023-08-16 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen and metabolites thereof by mass spectrometry
KR101571098B1 (ko) 2014-07-16 2015-11-23 건국대학교 산학협력단 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물
EP3230478B1 (en) * 2014-12-12 2023-08-02 Miradx Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
DK3449017T3 (da) 2016-04-29 2022-03-14 Univ Texas Målrettet måling af transkriptionel aktivitet vedrørende hormonreceptorer
TWI793165B (zh) 2017-09-11 2023-02-21 美商阿托薩醫療公司 製造及使用因多昔芬(endoxifen)之方法
US20210299094A1 (en) * 2018-07-24 2021-09-30 Cornell University Methods of upregulating tiparp as anticancer strategies
MX2022000203A (es) 2019-07-03 2022-03-22 Atossa Therapeutics Inc Composiciones de liberacion sostenida de endoxifeno.
CN121666379A (zh) * 2023-07-19 2026-03-13 阿托萨治疗学公司 抗肿瘤化合物及其使用方法和合成方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (https=) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
DE59703511D1 (de) * 1996-03-29 2001-06-13 S W Patentverwaltungs Ges M B Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der "cellulite"
EP1043986B1 (en) 1997-12-23 2003-04-16 Hexal Ag Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
NZ520015A (en) 1999-12-16 2003-03-28 Dermatrends Inc Hydroxide-releasing agents as skin permeation enhancers
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2003028667A2 (en) 2001-10-04 2003-04-10 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
DK1317921T3 (da) * 2001-12-07 2009-12-21 Besins Mfg Belgium Farmaceutisk sammensætning i form af en gel eller oplösning med dihydrotestosteron, fremgangsmåde til fremstilling og anvendelser heraf
DE60327363D1 (de) * 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
MXPA05006526A (es) * 2002-12-18 2006-02-17 Besins Int Lab Tratamiento de mastalgia con 4-hidroxi tamoxifen.
ES2456958T3 (es) 2003-04-01 2014-04-24 Besins Healthcare Luxembourg Sarl Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
JP4682129B2 (ja) * 2003-06-09 2011-05-11 アセンド セラピュティクス インコーポレイテッド ４−ヒドロキシタモキシフェンによる過剰瘢痕化の治療及び予防
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
WO2004087123A1 (en) 2004-10-14
US7704516B2 (en) 2010-04-27
JP5490346B2 (ja) 2014-05-14
NO20054526L (no) 2005-09-30
HK1119950A1 (en) 2009-03-20
ES2483896T3 (es) 2014-08-08
EP1952810B1 (en) 2014-01-08
EP1941871A1 (en) 2008-07-09
US20050031695A1 (en) 2005-02-10
EP1608353A1 (en) 2005-12-28
ES2456958T3 (es) 2014-04-24
ES2456957T3 (es) 2014-04-24
EP1608353B1 (en) 2014-04-30
HK1086193A1 (en) 2006-09-15
EP1941871B1 (en) 2014-01-08
CA2519980A1 (en) 2004-10-14
CA2519980C (en) 2012-04-10
AU2003294973A1 (en) 2004-10-25
NZ542499A (en) 2008-10-31
EP1952810A1 (en) 2008-08-06
NO333805B1 (no) 2013-09-16
AU2003294973B2 (en) 2010-05-13
JP2006514967A (ja) 2006-05-18
IL170807A (en) 2014-08-31
US20090186944A1 (en) 2009-07-23
US8475814B2 (en) 2013-07-02

Similar Documents

Publication Publication Date Title
MXPA05010597A (es) Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.
US10758514B2 (en) Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour
Bocca Supraglottic laryngectomy and functional neck dissection
Berkson et al. Revisiting the ALA/N (α-Lipoic Acid/Low-Dose Naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
RU2012148710A (ru) Органическое соединение для применения при лечении рака печени
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
Kästner et al. Removal of polyacrylamide gel (Aquamid®) from the lip as a solution for late-onset complications: our 8-year experience
EA201270298A1 (ru) Способ лечения злокачественной опухоли
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
NO20062904L (no) Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti
WO2002094199A3 (en) METHOD OF INCREASING ANTI-NeuGc ANTIBODY LEVELS IN BLOOD
SA94140746B1 (ar) مركب علاجي من /tamoxifen cisplatin للسرطانات في الانسان
PL1748770T3 (pl) Leczenie i zapobieganie dobrotliwej chorobie sutka 4-hydroksytamoksyfenem
Lee et al. Successful outcome of breast cancer patient refusing conventional treatments: A case report
US20140100174A1 (en) Treatment for Cancer
Baghi et al. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
Thorstad et al. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data
Nakashima et al. Selective (intra-arterial), rapid infusion chemo-radiotherapy to preserve the larynx in advanced laryngeal carcinoma: preliminary results
Stranadko et al. O7 Photodynamic therapy in esophageal cancer
Starr Venetoclax Shows Strong Activity in CLL
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease

Legal Events

Date Code Title Description
FG Grant or registration